First video, turning our Weekly Comm Discussion Topic into a video series
This week’s topic inspired by recent convos @ JPM:
Asked why I started Ticket to Biotech, what the impetus was.
How we landed on the model and programming where we’re at now is a diff convo.
What I want to focus on today is the uniqueness of what it means to do biopharma comms.
Our take is that biopharma comms and PR folks have to think about things that other comms pros don’t, like:
- operating in highly regulated industry
- complex science and technology
- it’s a long time until we’re consumer-facing- if at all
Like, debating whether or not to use the word “potentially” in comms materials is a perfectly normal thing for us to spend our time on. While I admittedly am not familiar with a lot of other kinds of PR, I don’t know another industry where using this word – or not – has serious legal and regulatory ramifications.
So, needless to say, we’re special, and that warrants a space for us to talk, vent, commiserate, learn and evolve. Voila, here we are.
Our community questions for you this week:
Tell me you do biopharma comms without telling me you do biopharma comms.
What are some of the things that you spend time thinking about that you suspect peers in other areas of PR or comms don’t? And are these areas where you could use support or you want to learn about others’ experiences?
Jump onto T2B Slack to tell us what you think.